Literature DB >> 18840815

The process to discover and develop biomarkers for cancer: a work in progress.

David F Ransohoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18840815     DOI： 10.1093/jnci/djn339

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  11 in total

1.  Randomized clinical trials with biomarkers: design issues.

Authors:  Boris Freidlin; Lisa M McShane; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2010-01-14       Impact factor: 13.506

2.  Biomarker Validation for Aging: Lessons from mtDNA Heteroplasmy Analyses in Early Cancer Detection.

Authors:  Peter E Barker; Mahadev Murthy
Journal:  Biomark Insights       Date:  2009-11-27

3.  A sample selection strategy to boost the statistical power of signature detection in cancer expression profile studies.

Authors:  Zhenyu Jia; Yipeng Wang; Yuanjie Hu; Christine McLaren; Yingyan Yu; Kai Ye; Xiao-Qin Xia; James A Koziol; Waldemar Lernhardt; Michael McClelland; Dan Mercola
Journal:  Anticancer Agents Med Chem       Date:  2013-02       Impact factor: 2.505

4.  Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.

Authors:  Sheri D Schully; Danielle M Carrick; Leah E Mechanic; Sudhir Srivastava; Garnet L Anderson; John A Baron; Christine D Berg; Jennifer Cullen; Eleftherios P Diamandis; V Paul Doria-Rose; Katrina A B Goddard; Susan E Hankinson; Lawrence H Kushi; Eric B Larson; Lisa M McShane; Richard L Schilsky; Steven Shak; Steven J Skates; Nicole Urban; Barnett S Kramer; Muin J Khoury; David F Ransohoff
Journal:  J Natl Cancer Inst       Date:  2015-02-16       Impact factor: 13.506

Review 5.  From differences in means between cases and controls to risk stratification: a business plan for biomarker development.

Authors:  Nicolas Wentzensen; Sholom Wacholder
Journal:  Cancer Discov       Date:  2013-01-08       Impact factor: 39.397

6.  Prediction of glycan motifs using quantitative analysis of multi-lectin binding: Motifs on MUC1 produced by cultured pancreatic cancer cells.

Authors:  Calvin McCarter; Doron Kletter; Huiyuan Tang; Katie Partyka; Yinjiao Ma; Sudhir Singh; Jessica Yadav; Marshall Bern; Brian B Haab
Journal:  Proteomics Clin Appl       Date:  2013-09-13       Impact factor: 3.494

7.  Sources of bias in specimens for research about molecular markers for cancer.

Authors:  David F Ransohoff; Margaret L Gourlay
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

Review 8.  What Tumor Dynamics Modeling Can Teach us About Exploiting the Stem-Cell View for Better Cancer Treatment.

Authors:  Roger S Day
Journal:  Cancer Inform       Date:  2015-02-24

9.  Use of semantic workflows to enhance transparency and reproducibility in clinical omics.

Authors:  Christina L Zheng; Varun Ratnakar; Yolanda Gil; Shannon K McWeeney
Journal:  Genome Med       Date:  2015-07-25       Impact factor: 11.117

10.  Planning clinically relevant biomarker validation studies using the "number needed to treat" concept.

Authors:  Roger S Day
Journal:  J Transl Med       Date:  2016-05-04       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.